A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2

References

• Hoffmann M, Kruger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–56e11.
   PubMed Web of Science ®Google Scholar
• Reardon S. How well can Omicron evade immunity from COVID vaccines? Nature. 2022. Epub 2022/02/03. doi: 10.1038/d41586-022-00283-4.
   Google Scholar
• Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nature. 2022;604(7906):553–556. doi:10.1038/s41586-022-04594-4.
   PubMed Web of Science ®Google Scholar
• Control ECfDPa. Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5. . https://wwwecdceuropaeu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba5. 2022.
   Google Scholar
• https://covid19.trackvaccines.org/. 2022.
   Google Scholar
• Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–2040. doi:10.1038/s41591-021-01540-1.
   PubMed Web of Science ®Google Scholar
• Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413, p1–9. doi:10.1126/sciimmunol.abc8413.
   PubMed Web of Science ®Google Scholar
• Kleanthous H, Silverman JM, Makar KW, et al. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. NPJ Vaccines. 2021;6(1):128, p1–10.
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–1119.
   PubMed Web of Science ®Google Scholar
• Dai L, Gao L, Tao L, et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N Engl J Med. 2022;386(22):2097–2111. doi: 10.1056/NEJMoa2202261.
   Google Scholar
• Boulton S, Poutou J, Martin NT, et al. Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection. Mol Ther. 2022;30(5):1885–1896.
   PubMed Web of Science ®Google Scholar
• Wang CY, Wang PN, Chiu MJ, et al. UB-311, a novel UBITh((R)) amyloid beta peptide vaccine for mild Alzheimer's disease. Alzheimers Dement (NY); 2017;3(2):262–272.
   PubMedGoogle Scholar
• Wang CY, Hwang KP, Kuo HK, et al. A multitope SARS-COV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J Clin Invest. 2022;132(10):e157707, p1-16. doi: 10.1172/JCI157707.
   Google Scholar
• Wang CY, Hwang KP, Kuo HK, et al. UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern. MedRxiv. 2022. https://doi.org/10.1101/2022.04.11.22272364.
   Google Scholar
• Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499–511.
   PubMed Web of Science ®Google Scholar
• Aborode AT, Fajemisin EA, Aiyenuro EA, et al. Neglected Tropical Diseases (NTDs) and COVID-19 pandemic in Africa: Special focus on control strategies. Comb Chem High Throughput Screen. 2022;25(14):2387–2390. doi: 10.2174/1386207325666220427123349.
   Google Scholar
• Sun CP, Jan JT, Wang IH, et al. Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. PLoS Pathog. 2021;17(8):e1009758, p1–27.
   Web of Science ®Google Scholar
• Munoz-Fontela C, Dowling WE, Funnell SGP, et al. Animal models for COVID-19. Nature. 2020;586(7830):509–515.
   PubMed Web of Science ®Google Scholar
• Rockx B, Kuiken T, Herfst S, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 2020;368(6494):1012–1015.
   PubMed Web of Science ®Google Scholar
• Guebre-Xabier M, Patel N, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38(50):7892–7896.
   PubMed Web of Science ®Google Scholar
• Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296, p1–20.
   PubMed Web of Science ®Google Scholar
• Weeratna RD, Brazolot Millan CL, McCluskie MJ, et al. Cpg ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol. 2001;32(1):65–71.
   PubMedGoogle Scholar
• Kotaki R, Adachi Y, Moriyama S, et al. SARS-CoV-2 omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. Sci Immunol. 2022;7(70):eabn8590, p1–10.
   Web of Science ®Google Scholar
• Schultz-Cherry S, McGargill MA, Thomas PG, et al. Cross-reactive antibody response to mRNA SARS-CoV-2 vaccine after recent COVID-19-specific monoclonal antibody therapy. Open Forum Infect Dis. 2021;8(9):ofab420, p1–4.
   Web of Science ®Google Scholar
• Schmitz AJ, Turner JS, Liu Z, et al. A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity. 2021;54(9):2159–66e6.
   PubMed Web of Science ®Google Scholar
• Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945–946.
   PubMed Web of Science ®Google Scholar
• Ricke DO. Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies. Front Immunol. 2021;12:640093, p1–9.
   Web of Science ®Google Scholar
• Wang Q, Zhang L, Kuwahara K, et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in Non-human primates. ACS Infect Dis. 2016;2(5):361–376.
   PubMed Web of Science ®Google Scholar
• Kuo TY, Lin MY, Coffman RL, et al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci Rep. 2020;10(1):20085, p1–10.
   PubMed Web of Science ®Google Scholar
• Ferreira L S, Canton O, da Silva RLP, et al. Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2. PLoS Comput Biol. 2022;18(3):e1009978, p1–15.
   Web of Science ®Google Scholar
• Pino M, Abid T, Pereira Ribeiro S, et al. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021;6:eabh3634, p1–18.
   Web of Science ®Google Scholar
• Sun S, He L, Zhao Z, et al. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice. Cell Mol Immunol. 2021;18(4):1070–1073.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Wang S, Wang CY, et al. High neutralizing antibody levels against SARS-CoV-2 omicron BA.1 and BA.2 after UB-612 vaccine booster. Journal of Infectious Disease. 2022;226(8):1401–1406.
   Google Scholar
• https://www.bangkokpost.com/thailand/general/2147667/sinovac-produced-antibodies-halve-every-40-days. 2022.
   Google Scholar
• Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N Engl J Med. 2021;384(23):2259–2261.
   PubMed Web of Science ®Google Scholar
• Suthar MS, Arunachalam PS, Hu M, et al. Durability of immune responses to the BNT162b2 mRNA vaccine. Med (N Y. 2022;3(1):25–27.
   PubMedGoogle Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med. 2021;2(7):100354, 1–e6.
   Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960.
   PubMed Web of Science ®Google Scholar